E N D
ChronicKidneyDisease Dr. Lakshminarayana GR
WhatisCKD? • Presence of markers of kidney damage for three months, as defined by structural or functional abnormalities of the kidney with or without decreased GFR, manifest by either pathological abnormalities or other markers of kidney damage, including abnormalities in the composition of blood or urine, or abnormalities inimaging tests. • The presence of GFR <60 mL/min/1.73 m2for threemonths,withorwithoutothersignsofkidney damageas describedabove. • AmJKidneyDis2002;39:S1
StagesofCKD • Stage1*:GFR>=90mL/min/1.73m2 • NormalorelevatedGFR • Stage2*:GFR60-89(mild) • Stage3:GFR30-59(moderate) • Stage4:GFR15-29(severe;pre-HD) • Stage5:GFR<15(kidneyfailure) • AmJKidneyDis2002;39(S2):S1-246
Otheretiologies • Renovasculardisease • Glomerulonephritis • Nephroticsyndrome • Hypercalcemia • Multiplemyeloma • ChronicUTI
Signs&Symptoms • General • Fatigue&malaise • Edema • Ophthalmologic • AVnicking • Cardiac • HTN • Heartfailure • Pericarditis • CAD • GI • Anorexia • Nausea/vomiting • Dysgeusia • Skin • Pruritis • Pallor • Neurological • MSchanges • Seizures
Hypertension • TargetBP • <130/80mmHg • <125/75mmHg • ⯈ptswithproteinuria(>1 g/d) • Consider several anti-HTN medications with differentmechanismsofactivity • ACEs/ARBs • Diuretics • CCBs • HCTZ(lesseffectivewhenGFR<20)
Proteinuria • Singlebestpredictorofdiseaseprogression • Normalalbuminexcretion • <30mg/24hours • Microalbuminuria • 20-200g/minor30-300mg/24hours • Macroalbuminuria • >300mg/24hours • Nephroticrangeproteinuria • >3g/24hours AmJKidneyDis2002;39(S2):S1-246
EvaluationforCKD • Blood • CBCwithdiff • SMA-7withCa2+and phosphorous • PTH • HBA1c • LFTsandFLP • UricacidandFe2+ studies • Urine • Urinalysis with microscopy • Spoturinefor microalbumin • 24-urine collection for proteinand creatinine • Ultrasound
Metabolicchanges with CKD • Hemoglobin/hematocrit • Bicarbonate • Calcium • Phosphate • PTH • Triglycerides
Anemia • CommoninCKD • HDpts have increased rates of: • Hospitaladmission • CAD/LVH • Reducedqualityoflife • Canimproveenergylevels,sleep,cognitive function, and quality of life in HD pts
Metabolicchanges… • Monitor and treat biochemicalabnormalities • Anemia • Metabolicacidosis • Mineralmetabolism • Dyslipidemia • Nutrition
TreatingAnemia • Epoetinalfa(rHuEPO;Epogen/Procrit) • HD:50-100U/kgIV/SC3x/wk • Non-HD:10,000Uqwk • Darbepoetinalfa(Aranesp) • HD:0.45g/kgIV/SCqwk • Non-HD:60gSCq2wks
Metabolicacidosis • Musclecatabolism • Metabolicbonedisease • Sodiumbicarbonate • Maintain serumbicarbonate >22meq/L • 0.5-1.0meq/kgperday • Watchforsodiumloading • ⯈Volumeexpansion • ⯈HTN
Mineralmetabolism • Calcium and phosphatemetabolism abnormalities associated with: • Renalosteodystrophy • Calciphylaxisandvascularcalcification • 14 of 16 ESRD/HD pts (20-30 yrs) had calcification on CT scan • 3of60inthe control group NEJM2000;342(20):1478-83
Dyslipidemia • Abnormalitiesinthelipidprofile • Triglycerides • Totalcholesterol • NCEPrecommendsreducinglipidlevelsin high-riskpopulations • Targets forlipid-loweringtherapyconsidered the same as those for the secondary preventionofCVdisease JAMA1993;269(23):3015-23
Nutrition • Thinkabouturemia • Catabolicstate • Anorexia • Decreasedproteinintake • Considerassistancewitharenaldietician
Management • Identify and treat factorsassociatedwith progressionof CKD • HTN • Proteinuria • Glucosecontrol